Folate Receptor Alpha (FRa) Prevalence In Platinum Resistant Ovarian Cancer From Phase 1 Studies Of The Novel Antibody Drug Conjugate, Luveltamab Tazevibulin (ESGO 2025) - Jan 5, 2025 - Abstract #172462; 301; Location: Poster area; P1, P2/3 | "It shows promise as both monotherapy and combination therapy with bevacizumab in women with platinum resistant ovarian cancer (PROC), including those with FRα-low to medium tumors. Conclusion Luvelta has the potential to become best-in-class FRα-tubulin-ADC and change the treatment landscape for ~8 of 10 women with FRα-positive PROC, including those with low to medium FRα expression. Luvelta is currently being evaluated in a pivotal phase 2/3 study in PROC patients with FRα ≥25% TPS (REFRαME-O1, STRO-002-GM3 [NCT05870748, ENGOT-OV79, GOG-3086, GEICO-134-O, APGOT-OV9])."
P1 data • Oncology • Ovarian Cancer • Solid Tumor • FOLR1
|
|
R. Wendel Naumann 1; Ana Oaknin 2; Lorena Fariñas-Madrid 2; Carmen Garcia-Duran 2; Lainie P. Martin 3; Bhavana Pothuri 4; Denise Uyar 5; John Paul Diaz 6; Alexander Spira 7; Jesus Garcia-Donas 8; Genevive Hernandez 9; Lin Lu 9; Craig Berman 9; David M. O'Malley 10
|